CFO Jürgen Esser said sales could be hit by up to 1% in the opening three months of 2026.

The CEO of French consumer goods giant Danone on Wednesday downplayed the threat of obesity drugs on its food business. Antoine de Saint-Affrique told CNBC that surging demand for drugs like Wegovy ...

French firms Danone and Nestlé saw a continued plunge in their share prices on Wednesday after a safety crisis involving baby formula. At around midday in Europe, Danone shares were down 0.48%, while ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Stymied in its takeover bid for Lifeway Foods, minority ...

By Alexander Marrow LONDON, Feb 18 (Reuters) - Nestle and Danone face investor pressure to spell out the financial impact of ...

Fourth-quarter sales topped estimates as protein demand strengthened, while infant formula recalls could trim first-quarter net sales by 0.5% to 1%.

Divestitures in Q1-2024 indicate that management continues to execute its “Renew Danone” plan, with a primary focus still on internal reorganization. Net income has been battered by extraordinary ...

Danone is undergoing a transformation with positive results, showing potential for a 13-16% annualized RoR. Danone remains an underperforming stock with a 2x variance compared to the market. Despite ...

As the early signs of GLP-1-driven disruption emerge in the food sector, more manufacturers are exploring weight management-friendly innovation. The shift isn’t seismic yet, but momentum is building.